Massachusetts Gov. Deval Patrick has incented biotech companies to move and grow in the state, but his $1 billion life sciences plan has failed to deliver on the ambitious jobs growth originally forecasted four years ago, The Boston Globe reports.
It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.
Sanofi is on track to find out whether its $20 billion deal for Genzyme will pay off with a near-term drug approval. The pharma giant says that Genzyme has submitted applications for the MS drug Lemtrada in both the U.S. and Europe. Bayer is partnered on the program.
Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its owner, Sanofi, are developing to compete in the blockbuster market for MS therapies that are swallowed rather than injected.
The company says in a release that the FDA and the EMA have given approval to a filling and finishing operation for Myozyme and Lumizyme, treatments for the enzyme deficiency known as Pompe disease.
In announcing the FDA approval of its new Gaucher disease treatment Elelyso, Pfizer put Genzyme firmly in its sights.
After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).
Sanofi had a good first quarter with higher revenues and profits, but executives acknowledge that the next 12 months will be tough.
Carl Icahn is turning up the heat on Amylin Pharmaceuticals' board of directors.
In an open letter, the feared raider lambasted the company for handing out stock options at $16 a share when it was keeping quiet about Bristol-Myers Squibb's $22 a share bid.